Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
manifesting similar oral and subcutaneous exposure in mice
Transl Perioper Pain Med
HDAC inhibitor SAHA
S3I-201 significantly reduces viable cell numbers and inhibits growth of transformed mouse fibroblasts NIH 3T3/v-Src and breast carcinoma cell lines (MDA-MB-231
TBA-354 Catalog No.:M8471-2 manifesting similar oral and subcutaneousTBA 354, also known as SN31354, is a potent anti tuberculosis drug candidate. TBA 354 is narrow spectrum and bactericidal in vitro against replicating and nonreplicating Mycobacterium tuberculosis, with potency similar to that of delamanid and greater than that of PA 824. TBA 354 maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains and clinical drug sensitive and drug resistant isolates. TBA 354 is a promising
US$ 156.50
US$ 795.00
US$ 505.00
US$ 1079.99
US$ 220.00